Mepolizumab

What it is used for

NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).

Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause.

Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1, 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids. Maintenance Treatment of Chronic Obstructive Pulmonary Disease NUCALA is indicated for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.

Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm. Eosinophilic Granulomatosis with Polyangiitis NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Hypereosinophilic Syndrome NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause.

Side effects, and when to stop

The following adverse reactions are described in greater detail in other sections:

• Hypersensitivity reactions
• Opportunistic infections: herpes zoster

Who should not take it

NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Other medicines and interactions

Formal drug interaction trials have not been performed with NUCALA.